Cellular and molecular effects of yeast probiotics on cancer

Critical Reviews in Microbiology

Volumn 43, Issue 1, 2017, Pages 96-115

  Saber, Amir ^a,b   Alipour, Beitollah ^b,c   Faghfoori, Zeinab ^d   Yari Khosroushahi, Ahmad ^b,e  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d SEMNAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

anti inflammation; anti proliferate; Anticancer; apoptosis; microbiota dysbiosis

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; BETA GLUCAN; FOLIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROBIOTIC AGENT;

ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; HUMAN; MICROFLORA; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; REVIEW; SPECIES COMPOSITION; YEAST; ANIMAL; GENETICS; GROWTH, DEVELOPMENT AND AGING; IMMUNOLOGY; INTESTINE FLORA; ISOLATION AND PURIFICATION; METABOLISM; MICROBIOLOGY; NEOPLASMS;

ANIMALS; GASTROINTESTINAL MICROBIOME; HUMANS; NEOPLASMS; PROBIOTICS; YEASTS;

EID: 85008444975     PISSN: 1040841X     EISSN: 15497828     Source Type: Journal    
DOI: 10.1080/1040841X.2016.1179622     Document Type: Review

References (276)

1. Adams M, Moss M. (2000). Food microbiology. 2nd ed. Cambridge:The Royal Society of Chemistry.
2. Aguilar‐Uscanga B, Francois J. (2003). A study of the yeast cell wall composition and structure in response to growth conditions and mode of cultivation. Let Appl Microbiol 37:268–74.
3. Algaba A, Guerra I, Marin-Jimenez I, et al. (2015). Incidence, management, and course of cancer in patients with inflammatory bowel disease. J Crohns Colitis 9:326–33.
4. Alvarez-Olmos MI, Oberhelman RA. (2001). Probiotic agents and infectious diseases:a modern perspective on a traditional therapy. Clin Infect Dis 32:1567–76.
5. Baba Y, Fujii M, Maeda T. (2015). Deguelin induces apoptosis by targeting both EGFR-Akt and IGF1R-Akt pathways in head and neck squamous cell cancer cell lines. BioMed Res Int 2015:657179.
6. Bailey RL, West KP, JrBlack RE. (2015). The epidemiology of global micronutrient deficiencies. Ann Nutr Metab 66:22–33.
7. Baines M, Kredan MB, Usher J, et al. (2007). The association of homocysteine and its determinants MTHFR genotype, folate, vitamin B12 and vitamin B6 with bone mineral density in postmenopausal British women. Bone 40:730–6.
8. Baldwin C, Millette M, Oth D, et al. (2010). Probiotic Lactobacillus acidophilus and L. casei mix sensitize colorectal tumoral cells to 5-fluorouracil-induced apoptosis. Nutr Cancer 62:371–8.
9. Balkwill F, Mantovani A. (2001). Inflammation and cancer:back to Virchow? Lancet 357:539–45.
10. Barouei J, Adams MC, Hodgson DM. (2009). Prophylactic role of maternal administration of probiotics in the prevention of irritable bowel syndrome. Med Hypothes 73:764–7.
11. Baum B, Liebler-Tenorio EM, Enss ML, et al. (2002). Saccharomyces boulardii and Bacillus cereus var. Toyoi influence the morphology and the mucins of the intestine of pigs. Z Gastroenterol 40:277–84.
12. Beermann C, Hartung J. (2013). Physiological properties of milk ingredients released by fermentation. Food Funct 4:185–99.
13. Belury MA. (2002). Inhibition of carcinogenesis by conjugated linoleic acid:potential mechanisms of action. J Nutr 132:2995–8.
14. Berger J, Moller DE. (2002). The mechanisms of action of PPARs. Annu Rev Med 53:409–35.
15. Bin Z, Ya-Zheng X, Zhao-Hui D, et al. (2015). The efficacy of Saccharomyces boulardii CNCM I-745 in addition to standard helicobacter pylori eradication treatment in children. Pediatr Gastroenterol Hepatol Nutr 18:17–22.
16. Bisson J-F, Hidalgo S, Rozan P, Messaoudi M. (2010). Preventive effects of different probiotic formulations on travelers’ diarrhea model in Wistar rats:preventive effects of probiotics on TD. Dig Dis Sci 55:911–19.
17. Borish LC, Steinke JW. (2003). Cytokines and chemokines. J Allergy Clin Immunol 111:S460–S75.
18. Brand CL, Sturis J, Gotfredsen CF, et al. (2003). Dual PPARalpha/gamma activation provides enhanced improvement of insulin sensitivity and glycemic control in ZDF rats. Am J Physiol Endocrinol Metab 284:E841–E54.
19. Brandao RL, Castro IM, Bambirra EA, et al. (1998). Intracellular signal triggered by cholera toxin in Saccharomyces boulardii and Saccharomyces cerevisiae. Appl Environ Microbiol 64:564–8.
20. Bromberg-White JL, Andersen NJ, Duesbery NS. (2012). MEK genomics in development and disease. Brief Funct Genomics 11:300–10.
21. Burns A, Rowland I. (2000). Anti-carcinogenicity of probiotics and prebiotics. Curr Issues Intest Microbiol 1:13–24.
22. Butler AR, White JH, Stark MJ. (1991). Analysis of the response of Saccharomyces cerevisiae cells to Kluyveromyces lactis toxin. J Gen Microbiol 137:1749–57.
23. Buts J-P, Bernasconi P, Vaerman JP, Dive C. (1990). Stimulation of secretory IgA and secretory component of immunoglobulins in small intestine of rats treated with Saccharomyces boulardii. Dig Dis Sci 35:251–6.
24. Buts J-P, Bernasconi P, van Craynest M-P, et al. (1986). Response of human and rat small intestinal mucosa to oral administration of Saccharomyces boulardii. Pediatr Res 20:192–6.
25. Buts J-P, de Keyser N. (2006). Effects of Saccharomyces boulardii on intestinal mucosa. Dig Dis Sci 51:1485–92.
26. Buts J-P, de Keyser N. (2010). Transduction pathways regulating the trophic effects of Saccharomyces boulardii in rat intestinal mucosa. Scand J Gastroenterol 45:175–85.
27. Buts J-P, de Keyser N, Marandi S, et al. (1999). Saccharomyces boulardii upgrades cellular adaptation after proximal enterectomy in rats. Gut 45:89–96.
28. Buts J-P, de Keyser N, Stilmant C, et al. (2002). Saccharomyces boulardii enhances N-terminal peptide hydrolysis in suckling rat small intestine by endoluminal release of a zinc-binding metalloprotease. Pediatr Res 51:528–34.
29. Buts J-P, de Keyser N, Stilmant C, et al. (2006). Saccharomyces boulardii produces in rat small intestine:a novel protein phosphatase that inhibits Escherichia coli endotoxin by dephosphorylation. Pediatr Res 60:24–9.
30. Buts J-P, Stilmant C, Bernasconi P, et al. (2008). Characterization of alpha, alpha-trehalase released in the intestinal lumen by the probiotic Saccharomyces boulardii. Scand J Gastroenterol 43:1489–96.
31. Candela M, Guidotti M, Fabbri A, et al. (2011). Human intestinal microbiota:cross-talk with the host and its potential role in colorectal cancer. Crit Rev Microbiol 37:1–14.
32. Cantley LC. (2002). The phosphoinositide 3-kinase pathway. Science 296:1655–7.
33. Carpenter K, Breslin W, Davidson T, et al. (2013). Baker’s yeast β-glucan supplementation increases monocytes and cytokines post-exercise:implications for infection risk? Br J Nutr 109:478–86.
34. Castagliuolo I, LaMont JT, Nikulasson ST, Pothoulakis C. (1996). Saccharomyces boulardii protease inhibits Clostridium difficile toxin A effects in the rat ileum. Infect Immun 64:5225–32.
35. Caunt CJ, Sale MJ, Smith PD, Cook SJ. (2015). MEK1 and MEK2 inhibitors and cancer therapy:the long and winding road. Nat Rev Cancer 15:577–92.
36. Ceapa C, Wopereis H, Rezaïki L, et al. (2013). Influence of fermented milk products, prebiotics and probiotics on microbiota composition and health. Best Pract Res Clin Gastroenterol 27:139–55.
37. Chan JY, Cheung JY, Luk SC, et al. (2004). Anti-cancer and pro-apoptotic effects of an herbal medicine and Saccharomyces cerevisiae product (CKBM) on human hepatocellular carcinoma HepG2 cells in vitro and in vivo. Immunopharmacol Immunotoxicol 26:597–609.
38. Chase D, Goulder A, Zenhausern F, et al. (2015). The vaginal and gastrointestinal microbiomes in gynecologic cancers:a review of applications in etiology, symptoms and treatment. Gynecol Oncol 138:190–200.
39. Chen P, Li C, Li X, et al. (2014). Higher dietary folate intake reduces the breast cancer risk:a systematic review and meta-analysis. Br J Cancer 110:2327–38.
40. Chen X, Fruehauf J, Goldsmith JD, et al. (2009). Saccharomyces boulardii inhibits EGF receptor signaling and intestinal tumor growth in Apc(min) mice. Gastroenterology 137:914–23.
41. Chen X, Kokkotou EG, Mustafa N, et al. (2006). Saccharomyces boulardii inhibits ERK1/2 mitogen-activated protein kinase activation both in vitro and in vivo and protects against Clostridium difficile toxin A-induced enteritis. J Biolog Chem 281:24449–54.
42. Chen X, Yang G, Song JH, et al. (2013). Probiotic yeast inhibits VEGFR signaling and angiogenesis in intestinal inflammation. PLoS One 8:e64227.
43. Chiu Y-H, Hsieh Y-J, Liao K-W, Peng K-C. (2010). Preferential promotion of apoptosis of monocytes by Lactobacillus casei rhamnosus soluble factors. Clin Nutr 29:131–40.
44. Choi CH, Jo SY, Park HJ, et al. (2011). A randomized, double-blind, placebo-controlled multicenter trial of Saccharomyces boulardii in irritable bowel syndrome:effect on quality of life. J Clin Gastroenterol 45:679–83.
45. Choi SW, Mason JB. (2000). Folate and carcinogenesis:an integrated scheme. J Nutr 130:129–32.
46. Chong ES. (2014). A potential role of probiotics in colorectal cancer prevention:review of possible mechanisms of action. World J Microbiol Biotechnol 30:351–74.
47. Cindoruk M, Erkan G, Karakan T, et al. (2007). Efficacy and safety of Saccharomyces boulardii in the 14-day triple anti-Helicobacter pylori therapy:a prospective randomized placebo-controlled double-blind study. Helicobacter 12:309–16.
48. Collier CT, Carroll JA, Ballou MA, et al. (2011). Oral administration of Saccharomyces cerevisiae boulardii reduces mortality associated with immune and cortisol responses to Escherichia coli endotoxin in pigs. J Anim Sci 89:52–8.
49. Cousin FJ, Jouan-Lanhouet S, Dimanche-Boitrel M-T, et al. (2012). Milk fermented by Propionibacterium freudenreichii induces apoptosis of HGT-1 human gastric cancer cells. PLoS One 7:e31892.
50. Coussens LM, Werb Z. (2002). Inflammation and cancer. Nature 420:860–7.
51. Czerucka D, Piche T, Rampal P. (2007). Review article:yeast as probiotics–Saccharomyces boulardii. Aliment Pharmacol Therapeut 26:767–78.
52. Czerucka D, Rampal P. (2002). Experimental effects of Saccharomyces boulardii on diarrheal pathogens. Microbes Infect 4:733–9.
53. da Silva JF, Peluzio JM, Prado G, et al. (2015). Use of probiotics to control aflatoxin production in peanut grains. ScientificWorldJournal 2015:959138.
54. Dahan S, Dalmasso G, Imbert V, et al. (2003). Saccharomyces boulardii interferes with enterohemorrhagic Escherichia coli-induced signaling pathways in T84 cells. Infect Immun 71:766–73.
55. Dalmasso G, Cottrez F, Imbert V, et al. (2006a). Saccharomyces boulardii inhibits inflammatory bowel disease by trapping T cells in mesenteric lymph nodes. Gastroenterol 131:1812–25.
56. Dalmasso G, Loubat A, Dahan S, et al. (2006b). Saccharomyces boulardii prevents TNF-alpha-induced apoptosis in EHEC-infected T84 cells. Res Microbiol 157:456–65.
57. Daniluk U. (2012). Probiotics, the new approach for cancer prevention and/or potentialization of anti-cancer treatment? J Clin Exp Oncol. 1:2. doi:10.4172/2324-9110.1000e105.
58. de Batlle J, Ferrari P, Chajes V, et al. (2015). Dietary folate intake and breast cancer risk:European prospective investigation into cancer and nutrition. J Natl Cancer Inst 107:367.
59. de Jong JS, van Diest PJ, van der Valk P, Baak JP. (1998). Expression of growth factors, growth-inhibiting factors, and their receptors in invasive breast cancer. II:correlations with proliferation and angiogenesis. J Pathol 184:53–7.
60. de Martel C, Ferlay J, Franceschi S, et al. (2012). Global burden of cancers attributable to infections in 2008:a review and synthetic analysis. Lancet Oncol 13:607–15.
61. Demir G, Klein HO, Mandel-Molinas N, Tuzuner N. (2007). Beta glucan induces proliferation and activation of monocytes in peripheral blood of patients with advanced breast cancer. Int Immunopharmacol 7:113–16.
62. Di Luzio NR, Williams DL, McNamee RB, et al. (1979). Comparative tumor-inhibitory and anti-bacterial activity of soluble and particulate glucan. Int J Cancer 24:773–9.
63. Du C, Fang M, Li Y, et al. (2000). Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 102:33–42.
64. Duthie SJ. (1999). Folic acid deficiency and cancer:mechanisms of DNA instability. Br Med Bull 55:578–92.
65. Everard A, Matamoros S, Geurts L, et al. (2014). Saccharomyces boulardii administration changes gut microbiota and reduces hepatic steatosis, low-grade inflammation, and fat mass in obese and type 2 diabetic db/db mice. MBio 5:e01011–14.
66. Farrell JJ, Zhang L, Zhou H, et al. (2012). Variations of oral microbiota are associated with pancreatic diseases including pancreatic cancer. Gut 61:582–8.
67. Feige JN, Gelman L, Michalik L, et al. (2006). From molecular action to physiological outputs:peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions. Prog Lipid Res 45:120–59.
68. Fernandez M, Hudson JA, Korpela R. (2015). Impact on human health of microorganisms present in fermented dairy products:an overview. Biomed Res Int 2015:412714.
69. Figueiredo JC, Grau MV, Haile RW, et al. (2009). Folic acid and risk of prostate cancer:results from a randomized clinical trial. JNCI 101:432–5.
70. Finegood DT, McArthur MD, Kojwang D, et al. (2001). Beta-cell mass dynamics in Zucker diabetic fatty rats. Rosiglitazone prevents the rise in net cell death. Diabetes 50:1021–9.
71. Fleet G, Balia R. 2006. The public health and probiotic significance of yeasts in foods and beverages. Berlin, Heidelberg:Springer.
72. Fogg C, Kasliwal R, Shakir SA. (2009). Risk management and outcomes of adverse events to pioglitazone in primary care in the UK:an observational study. Drug Saf 32:229–37.
73. Foligne B, Dewulf J, Vandekerckove P, et al. (2010). Probiotic yeasts:anti-inflammatory potential of various non-pathogenic strains in experimental colitis in mice. World J Gastroenterol 16:2134–45.
74. Fooks LJ, Gibson GR. (2002). Probiotics as modulators of the gut flora. Br J Nutr 88:S39–49.
75. Friedman G. (2012). The role of probiotics in the prevention and treatment of antibiotic-associated diarrhea and Clostridium difficile colitis. Gastroenterol Clin North Am 41:763–79.
76. Fukata M, Abreu MT. (2010). Microflora in colorectal cancer:a friend to fear. Nat Med 16:639–41.
77. Fuller R. (1991). Probiotics in human medicine. Gut 32:439.
78. Garcia Vilela E, de Lourdes de Abreu Ferrari M, Oswaldo Da Gama Torres H, et al. (2008). Influence of Saccharomyces boulardii on the intestinal permeability of patients with Crohn’s disease in remission. Scand J Gastroenterol 43:842–8.
79. Gedek B. (1999). Adherence of Escherichia coli serogroup 0 157 and the Salmonella typhimurium mutant DT 104 to the surface of Saccharomyces boulardii. [Adhärenz von Escherichia coli Serogruppe 0 157 und von der Salmonella typhimurium-Mutante DT 104 an der Oberfläche.] Mycoses 42:261–4.
80. Geier MS, Butler RN, Howarth GS. (2007). Inflammatory bowel disease:current insights into pathogenesis and new therapeutic options; probiotics, prebiotics and synbiotics. Int J Food Microbiol 115:1–11.
81. Ghoneum M, El-Din NKB, Noaman E, Tolentino L. (2008a). Saccharomyces cerevisiae, the baker’s yeast, suppresses the growth of Ehrlich carcinoma-bearing mice. Cancer Immunol Immunother 57:581–92.
82. Ghoneum M, Gollapudi S. (2004). Induction of apoptosis in breast cancer cells by Saccharomyces cerevisiae, the baker’s yeast, in vitro. Anticancer Res 24:1455–64.
83. Ghoneum M, Gollapudi S. (2005). Synergistic role of arabinoxylan rice bran (MGN-3/Biobran) in S. cerevisiae-induced apoptosis of monolayer breast cancer MCF-7 cells. Anticancer Res 25:4187–96.
84. Ghoneum M, Hamilton J, Brown J, Gollapudi S. (2005). Human squamous cell carcinoma of the tongue and colon undergoes apoptosis upon phagocytosis of Saccharomyces cerevisiae, the baker’s yeast, in vitro. Anticancer Res 25:981–9.
85. 2+ and the ratio of Bax and Bcl-2. Int J Oncol 33:533–9.
86. Giordano A, Rustum YM, Wenner CE. (1998). Cell cycle:molecular targets for diagnosis and therapy:tumor suppressor genes and cell cycle progression in cancer. J Cell Biochem 70:1–7.
87. Girard P, Pansart Y, Gillardin JM. (2005). Inducible nitric oxide synthase involvement in the mechanism of action of Saccharomyces boulardii in castor oil-induced diarrhoea in rats. Nitric Oxide 13:163–9.
88. Girardin M, Seidman EG. (2011). Indications for the use of probiotics in gastrointestinal diseases. Dig Dis 29:574–87.
89. Goel S, Hidalgo M, Perez-Soler R. (2007). EGFR inhibitor-mediated apoptosis in solid tumors. J Exp Ther Oncol 6:305–20.
90. Goncalves AM, Pedro AQ, Maia C, et al. (2013). Pichia pastoris:a recombinant microfactory for antibodies and human membrane proteins. J Microbiol Biotechnol 23:587–601.
91. Goodsell DS. (2002). The molecular perspective:Bcl-2 and apoptosis. Oncologist 7:259–60.
92. Gregory J. (1996). Vitamins. In:Fennema OR, ed. Food chemistry. 3rd ed. New York:Marcel Dekker, 532.
93. Greten FR, Eckmann L, Greten TF, et al. (2004). IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 118:285–96.
94. Gui QF, Lu HF, Zhang CX, et al. (2015). Well-balanced commensal microbiota contributes to anti-cancer response in a lung cancer mouse model. Genet Mol Res 14:5642–51.
95. Haghshenas B, Abdullah N, Nami Y, et al. (2014). Different effects of two newly-isolated probiotic Lactobacillus plantarum 15HN and Lactococcus lactis subsp. Lactis 44Lac strains from traditional dairy products on cancer cell lines. Anaerobe 30:51–9.
96. Hanson AD, Roje S. (2001). One-carbon metabolism in higher plants. Annu Rev Plant Physiol Plant Mol Biol 52:119–37.
97. Hatoum R, Labrie S, Fliss I. (2012a). Antimicrobial and probiotic properties of yeasts:from fundamental to novel applications. Front Microbiol 3:421.
98. Hatoum R, Labrie S, Fliss I. (2012b). Antimicrobial and probiotic properties of yeasts:from fundamental to novel applications. Front Microbiol 3:1–12.
99. Hirayama K, Rafter J. (2000). The role of probiotic bacteria in cancer prevention. Microbes Infect 2:681–6.
100. Hjortmo S, Patring J, Andlid T. (2008a). Growth rate and medium composition strongly affect folate content in Saccharomyces cerevisiae. Int J Food Microbiol 123:93–100.
101. Hjortmo S, Patring J, Jastrebova J, Andlid T. (2005). Inherent biodiversity of folate content and composition in yeasts. Trends Food Sci Technol 16:311–16.
102. Hjortmo SB, Hellström AM, Andlid TA. (2008b). Production of folates by yeasts in Tanzanian fermented togwa. FEMS Yeast Res 8:781–7.
103. Hofer M, Pospíšil M. (1997). Glucan as stimulator of hematopoiesis in normal and gamma-irradiated mice. A survey of the authors’ results. Int J Immunopharmacol 19:607–9.
104. Hoffman FA, Heimbach JT, Sanders ME, Hibberd PL. (2008). Executive summary:scientific and regulatory challenges of development of probiotics as foods and drugs. Clin Inf Dis 46:S53–7.
105. Holzapfel WH, Schillinger U. (2002). Introduction to pre-and probiotics. Food Res Int 35:109–16.
106. Hong F, Hansen RD, Yan J, et al. (2003). Beta-glucan functions as an adjuvant for monoclonal antibody immunotherapy by recruiting tumoricidal granulocytes as killer cells. Cancer Res 63:9023–31.
107. Hong MY, Henning S, Moro A, et al. (2011). Chinese red yeast rice inhibition of prostate tumor growth in SCID mice. Cancer Prev Res (Phila) 4:608–15.
108. Hong MY, Seeram N, Heber D. (2007). Matrix effects of Chinese red yeast rice beyond monacolin K alone in colon cancer cells. Cancer Res 67:4989.
109. Hubmacher D, Cirulis JT, Miao M, et al. (2010). Functional consequences of homocysteinylation of the elastic fiber proteins fibrillin-1 and tropoelastin. J Biol Chem 285:1188–98.
110. Hunter K, Gault R, Berner M. (2002). Preparation of microparticulate beta-glucan from Saccharomyces cerevisiae for use in immune potentiation. Lett Appl Microbiol 35:267–71.
111. Icaza-Chavez ME. (2013). [Gut microbiota in health and disease]. Rev Gastroenterol Mex 78:240–8.
112. Iyer C, Kosters A, Sethi G, et al. (2008). Probiotic Lactobacillus reuteri promotes TNF-induced apoptosis in human myeloid leukemia-derived cells by modulation of NF-kappaB and MAPK signalling. Cell Microbiol 10:1442–52.
113. Jaiswal M, LaRusso NF, Burgart LJ, Gores GJ. (2000). Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism. Cancer Res 60:184–90.
114. Javmen A, Grigiškis S, Gliebutė R. (2012). β-glucan extraction from Saccharomyces cerevisiae yeast using Actinomyces rutgersensis 88 yeast lyzing enzymatic complex. Biologija 58:51–9.
115. Javmen A, Grigiškis S, Rudenkov M, Mauricas M. (2013). Purification and partial characterization of a novel β-1,3-endoglucanase from Streptomyces rutgersensis. Protein J 32:411–17.
116. Javmen A, Nemeikaite-Ceniene A, Bratchikov M, et al. (2015a). β-Glucan from Saccharomyces cerevisiae induces IFN-γ production in vivo in BALB/c mice. In Vivo 29:359–63.
117. Javmen A, Nemeikaitè-Cènienè A, Grigiškis S, et al. (2015b). S. cerevisiae β-glucan reduced viability of mouse hepatoma cells in vitro. Turkish J Biol 39:562–66.
118. Jawhara S, Poulain D. (2007). Saccharomyces boulardii decreases inflammation and intestinal colonization by Candida albicans in a mouse model of chemically-induced colitis. Med Mycol 45:691–700.
119. Jimeno A, Hidalgo M. (2006). Pharmacogenomics of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. Biochim Biophys Acta Mol Cell Res 1766:217–29.
120. Kamada N, Seo SU, Chen GY, Nunez G. (2013). Role of the gut microbiota in immunity and inflammatory disease. Nat Rev Immunol 13:321–35.
121. Karen M, Yuksel O, Akyürek N, et al. (2010). Probiotic agent Saccharomyces boulardii reduces the incidence of lung injury in acute necrotizing pancreatitis induced rats. J Surg Res 160:139–44.
122. Kariluoto S, Aittamaa M, Korhola M, et al. (2006). Effects of yeasts and bacteria on the levels of folates in rye sourdoughs. Int J Food Microbiol 106:137–43.
123. Kim YI. (2005). Nutritional epigenetics:impact of folate deficiency on DNA methylation and colon cancer susceptibility. J Nutr 135:2703–9.
124. Kim YI. (2006a). Does a high folate intake increase the risk of breast cancer? Nutr Rev 64:468–75.
125. Kim YI. (2006b). Folate:a magic bullet or a double edged sword for colorectal cancer prevention? Gut 55:1387–9.
126. Kim YI. (2007). Folate and colorectal cancer:an evidence-based critical review. Mol Nutr Food Res 51:267–92.
127. Klaenhammer T, Doyle M, Beuchat L. (2007). Probiotics and prebiotics. Food Microbiol Fundam Front Edn 3:891–907.
128. Klingberg TD, Lesnik U, Arneborg N, et al. (2008). Comparison of Saccharomyces cerevisiae strains of clinical and nonclinical origin by molecular typing and determination of putative virulence traits. FEMS Yeast Res 8:631–40.
129. Kogan G, Pajtinka M, Babincova M, et al. (2008). Yeast cell wall polysaccharides as antioxidants and antimutagens:can they fight cancer? Neoplasma 55:387–93.
130. Konings EJ, Troost FJ, Castenmiller JJ, et al. (2002). Intestinal absorption of different types of folate in healthy subjects with an ileostomy. Br J Nutr 88:235–42.
131. Korhola M, Hakonen R, Juuti K, et al. (2014). Production of folate in oat bran fermentation by yeasts isolated from barley and diverse foods. J Appl Microbiol 117:679–89.
132. Korhonen R, Lahti A, Kankaanranta H, Moilanen E. (2005). Nitric oxide production and signaling in inflammation. Curr Drug Targets Inflamm Allergy 4:471–9.
133. Krizkova L, Durackova Z, Sandula J, et al. (2001). Antioxidative and antimutagenic activity of yeast cell wall mannans in vitro. Mutat Res 497:213–22.
134. Kroemer G, Reed JC. (2000). Mitochondrial control of cell death. Nat Med 6:513–19.
135. Kumar M, Nagpal R, Verma V, et al. (2013). Probiotic metabolites as epigenetic targets in the prevention of colon cancer. Nutr Rev 71:23–34.
136. 1-induced liver carcinogenesis in rats. Br J Nutr 107:1006–16.
137. Kumura H, Tanoue Y, T M, et al. (2004). Screening of dairy yeast strains for probiotic applications. J Dairy Sci 87:4050–6.
138. Kuniyasu H, Yoshida K, Sasaki T, et al. (2006). Conjugated linoleic acid inhibits peritoneal metastasis in human gastrointestinal cancer cells. Int J Cancer 118:571–6.
139. Laroche C, Michaud P. (2007). New developments and prospective applications for β (1,3) glucans. Recent Patents Biotechnol 1:59–73.
140. LeBlanc JG, de Giori GS, Smid EJ, et al. (2007). Folate production by lactic acid bacteria and other food-grade microorganisms. Commun Curr Res Edu Topics Trends Appl Microbiol 1:329–39.
141. Lee SK, Kim HJ, Chi SG, et al. (2005). [Saccharomyces boulardii activates expression of peroxisome proliferator-activated receptor-gamma in HT-29 cells]. Korean J Gastroenterol 45:328–34.
142. Lessard M, Dupuis M, Gagnon N, et al. (2009). Erratum to “Administration of Pediococcus acidilactici or Saccharomyces cerevisiae boulardii modulates development of porcine mucosal immunity and reduces intestinal bacterial translocation after Escherichia coli challenge”. J Anim Sci 87:922–34.
143. Lewis TS, Shapiro PS, Ahn NG. (1998). Signal transduction through MAP kinase cascades. Adv Cancer Res 74:49–139.
144. Lim BK, Mahendran R, Lee YK, Bay BH. (2002). Chemopreventive effect of Lactobacillus rhamnosus on growth of a subcutaneously implanted bladder cancer cell line in the mouse. Jpn J Cancer Res 93:36–41.
145. Lim MH, Lee OH, Chin JE, et al. (2008). Simultaneous degradation of phytic acid and starch by an industrial strain of Saccharomyces cerevisiae producing phytase and alpha-amylase. Biotechnol Lett 30:2125–30.
146. Lin EY, Pollard JW. (2004). Macrophages:modulators of breast cancer progression. Novartis Found Symp 256:158–68. discussion 68-72, 259-69.
147. Linhart HG, Troen A, Bell GW, et al. (2009). Folate deficiency induces genomic uracil misincorporation and hypomethylation but does not increase DNA point mutations. Gastroenterology 136:227–35.e3.
148. Liu Z, Choi SW, Crott JW, et al. (2007). Mild depletion of dietary folate combined with other B vitamins alters multiple components of the Wnt pathway in mouse colon. J Nutr 137:2701–8.
149. Liu Z, Choi SW, Crott JW, et al. (2008). Multiple B-vitamin inadequacy amplifies alterations induced by folate depletion in p53 expression and its downstream effector MDM2. Int J Cancer 123:519–25.
150. Low YL, Hwang PL. (1995). Lymphoma cells selected for resistance against the cytotoxic effect of oxygenated sterols are also resistant to nonsteroidal antiestrogens. Biochim Biophys Acta Mol Cell Res 1269:32–40.
151. MacGregor JT, Schlegel R, Wehr CM, et al. (1990). Cytogenetic damage induced by folate deficiency in mice is enhanced by caffeine. Proc Natl Acad Sci USA 87:9962–5.
152. Madrigal-Santillan E, Madrigal-Bujaidar E, Marquez-Marquez R, Reyes A. (2006). Antigenotoxic effect of Saccharomyces cerevisiae on the damage produced in mice fed with aflatoxin B(1) contaminated corn. Food Chem Toxicol 44:2058–63.
153. Malfertheiner P, Selgrad M, Bornschein J. (2012). Helicobacter pylori:clinical management. Curr Opin Gastroenterol 28:608–14.
154. Margeli A, Kouraklis G, Theocharis S. (2003). Peroxisome proliferator activated receptor-gamma (PPAR-gamma) ligands and angiogenesis. Angiogenesis 6:165–9.
155. Marteau P, Boutron-Ruault M. (2002). Nutritional advantages of probiotics and prebiotics. Brit J Nutr 87:S153–S7.
156. Martinac B, Zhu H, Kubalski A, et al. (1990). Yeast K1 killer toxin forms ion channels in sensitive yeast spheroplasts and in artificial liposomes. Proc Natl Acad Sci USA 87:6228–32.
157. Martins AK, Martins FS, Gomes DA, et al. (2010a). Evaluation of in vitro antagonism and of in vivo immune modulation and protection against pathogenic experimental challenge of two probiotic strains of Bifidobacterium animalis var. lactis. Arch Microbiol 192:995–1003.
158. Martins FS, Dalmasso G, Arantes RM, et al. (2010b). Interaction of Saccharomyces boulardii with Salmonella enterica serovar Typhimurium protects mice and modifies T84 cell response to the infection. PLoS One 5:e8925.
159. Martins FS, Elian SD, Vieira AT, et al. (2011). Oral treatment with Saccharomyces cerevisiae strain UFMG 905 modulates immune responses and interferes with signal pathways involved in the activation of inflammation in a murine model of typhoid fever. Int J Med Microbiol 301:359–64.
160. Martins FS, Vieira AT, Elian SD, et al. (2013). Inhibition of tissue inflammation and bacterial translocation as one of the protective mechanisms of Saccharomyces boulardii against Salmonella infection in mice. Microbes Infect 15:270–9.
161. Maruti SS, Ulrich CM, White E. (2009). Folate and one-carbon metabolism nutrients from supplements and diet in relation to breast cancer risk. Am J Clin Nutr 89:624–33.
162. Mason JB. (2009). Folate, cancer risk, and the Greek god, Proteus:a tale of two chameleons. Nutr Rev 67:206–12.
163. Mason R. (2001). What is beta-glucan? In:Safe goods. Sheffield, MA:New Century Publishing, 4–36.
164. Maynard CL, Elson CO, Hatton RD, Weaver CT. (2012). Reciprocal interactions of the intestinal microbiota and immune system. Nature 489:231–41.
165. McFarland LV. (2007). Meta-analysis of probiotics for the prevention of traveler’s diarrhea. Travel Med Infect Dis 5:97–105.
166. McFarland LV. (2010). Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. World J Gastroenterol 16:2202.
167. McFarlin BK, Carpenter KC, Davidson T, McFarlin MA. (2013). Baker’s yeast beta glucan supplementation increases salivary IgA and decreases cold/flu symptomatic days after intense exercise. J Diet Suppl 10:171–83.
168. Mirone G, Shukla A, Marfe G. (2015). Signaling mechanisms of resistance to EGFR- and anti-angiogenic inhibitors cancer. Crit Rev Oncol Hematol 97:85–95.
169. Mooradian AD, Chehade J, Thurman JE. (2002). The role of thiazolidinediones in the treatment of patients with type 2 diabetes mellitus. Treat Endocrinol 1:13–20.
170. Moslehi-Jenabian S, Lindegaard L, Jespersen L. (2010). Beneficial effects of probiotic and food borne yeasts on human health. Nutrients 2:449–73.
171. Motomura W, Nagamine M, Tanno S, et al. (2004). Inhibition of cell invasion and morphological change by troglitazone in human pancreatic cancer cells. J Gastroenterol 39:461–8.
172. Mumy KL, Chen X, Kelly CP, McCormick BA. (2008). Saccharomyces boulardii interferes with Shigella pathogenesis by postinvasion signaling events. Am J Physiol Gastrointest Liver Physiol 294:G599–609.
173. Naito S, Koga H, Yamaguchi A, et al. (2008). Prevention of recurrence with epirubicin and Lactobacillus casei after transurethral resection of bladder cancer. J Urol 179:485–90.
174. Nami Y, Abdullah N, Haghshenas B, et al. (2014). Probiotic potential and biotherapeutic effects of newly isolated vaginal Lactobacillus acidophilus 36YL strain on cancer cells. Anaerobe 28:29–36.
175. Norton L. (1988). A Gompertzian model of human breast cancer growth. Cancer Res 48:7067–71.
176. Novak M, Vetvicka V. (2009). Glucans as biological response modifiers. Endocr Metab Immune Disord Drug Targets 9:67–75.
177. Nowak A, Slizewska K, Otlewska A. (2015). Antigenotoxic activity of lactic acid bacteria, prebiotics, and products of their fermentation against selected mutagens. Regul Toxicol Pharmacol 73:938–46.
178. Nurmi JT, Puolakkainen PA, Rautonen NE. (2005). Bifidobacterium lactis sp. 420 up-regulates cyclooxygenase (Cox)-1 and down-regulates Cox-2 gene expression in a Caco-2 cell culture model. Nutr Cancer 51:83–92.
179. O’Horo JC, Jindai K, Kunzer B, Safdar N. (2014). Treatment of recurrent Clostridium difficile infection:a systematic review. Infection 42:43–59.
180. Oliveira RJ, Matuo R, da Silva AF, et al. (2007). Protective effect of beta-glucan extracted from Saccharomyces cerevisiae, against DNA damage and cytotoxicity in wild-type (k1) and repair-deficient (xrs5) CHO cells. Toxicol in Vitro 21:41–52.
181. Oliveira RJ, Salles MJ, da Silva AF, et al. (2013). In vivo evaluation of the antimutagenic and antigenotoxic effects of β-glucan extracted from Saccharomyces cerevisiae in acute treatment with multiple doses. Genet Mol Biol 36:413–24.
182. Olstorpe M, Schnürer J, Passoth V. (2009). Screening of yeast strains for phytase activity. FEMS Yeast Res 9:478–88.
183. Ooi CY, Dilley AV, Day AS. (2009). Saccharomyces boulardii in a child with recurrent Clostridium difficile. Pediatr Int 51:156–8.
184. Palma M, Zamith-Miranda D, Martins F, et al. (2015). Probiotic Saccharomyces cerevisiae strains as biotherapeutic tools:is there room for improvement? Appl Microbiol Biotechnol 99:6563–70.
185. Patring JD, Hjortmo SB, Jastrebova JA, et al. (2006). Characterization and quantification of folates produced by yeast strains isolated from kefir granules. Eur Food Res Technol 223:633–7.
186. Patring JD, Jastrebova JA, Hjortmo SB, et al. (2005). Development of a simplified method for the determination of folates in baker’s yeast by HPLC with ultraviolet and fluorescence detection. J Agric Food Chem 53:2406–11.
187. Pelizon A, Kaneno R, Soares A, et al. (2005). Immunomodulatory activities associated with β-glucan derived from Saccharomyces cerevisiae. Physiol Res 54:557–64.
188. Perla-Kajan J, Jakubowski H. (2010). Paraoxonase 1 protects against protein N-homocysteinylation in humans. FASEB J 24:931–6.
189. Péteri Z, Téren J, Vágvölgyi C, Varga J. (2007). Ochratoxin degradation and adsorption caused by astaxanthin-producing yeasts. Food Microbiol 24:205–10.
190. Petravić-Tominac V, Zechner-Krpan V, Grba S, et al. (2010). Biological effects of yeast β-glucans. Agric Consp Sci 75:149–58.
191. Pfeilschifter J, Eberhardt W, Beck KF. (2001). Regulation of gene expression by nitric oxide. Pflugers Arch 442:479–86.
192. Philpott DJ, McKay DM, Sherman PM, Perdue MH. (1996). Infection of T84 cells with enteropathogenic Escherichia coli alters barrier and transport functions. Am J Physiol 270:G634–45.
193. Pickavance LC, Widdowson PS, Foster JR, et al. (2003). Chronic treatment with the thiazolidinedione, MCC-555, is associated with reductions in nitric oxide synthase activity and beta-cell apoptosis in the pancreas of the Zucker Diabetic Fatty rat. Int J Exp Pathol 84:83–9.
194. Pithva SP, Ambalam PS, Ramoliya JM, et al. (2015). Antigenotoxic and antimutagenic activities of probiotic Lactobacillus rhamnosus Vc against N-methyl-N′-nitro-N-nitrosoguanidine. Nutr Cancer 67:1142–50.
195. Plaza-Diaz J, Gomez-Llorente C, Fontana L, Gil A. (2014). Modulation of immunity and inflammatory gene expression in the gut, in inflammatory diseases of the gut and in the liver by probiotics. World J Gastroenterol 20:15632–49.
196. Pontier-Bres R, Munro P, Boyer L, et al. (2014). Saccharomyces boulardii modifies Salmonella typhimurium traffic and host immune responses along the intestinal tract. PLoS One 9:e103069.
197. Ponz-Sarvise M, Rodriguez J, Viudez A, et al. (2007). Epidermal growth factor receptor inhibitors in colorectal cancer treatment:what’s new? World J Gastroenterol 13:5877–87.
198. Pothoulakis C. (2009). Review article:anti-inflammatory mechanisms of action of Saccharomyces boulardii. Aliment Pharmacol Ther 30:826–33.
199. Prasad V, Goldstein JA. (2014). US News and World Report cancer hospital rankings:do they reflect measures of research productivity? PLoS One 9:e107803.
200. Psani M, Kotzekidou P. (2006). Technological characteristics of yeast strains and their potential as starter adjuncts in Greek-style black olive fermentation. World J Microbiol Biotechnol 22:1329–36.
201. Qamar A, Aboudola S, Warny M, et al. (2001). Saccharomyces boulardii stimulates intestinal immunoglobulin A immune response to Clostridium difficile toxin A in mice. Infect Immun 69:2762–5.
202. Rafter J. (2003). Probiotics and colon cancer. Best Pract Res Clin Gastroenterol 17:849–59.
203. Ragon M, Aumelas A, Chemardin P, et al. (2008). Complete hydrolysis of myo-inositol hexakisphosphate by a novel phytase from Debaryomyces castellii CBS 2923. Appl Microbiol Biotechnol 78:47–53.
204. Ravi Subbiah M, Abplanalp W. (2003). Ergosterol (major sterol of baker’s and brewer’s yeast extracts) inhibits the growth of human breast cancer cells in vitro and the potential role of its oxidation products. Int J Vit Nutr Res 73:19–23.
205. Reddy BS, Weisburger JH, Narisawa T, Wynder EL. (1974). Colon carcinogenesis in germ-free rats with 1,2-dimethylhydrazine and N-methyl-N′-nitro-N-nitrosoguanidine. Cancer Res 34:2368–72.
206. Reisenauer AM, Halsted CH. (1987). Human folate requirements. J Nutr 117:600–2.
207. Rogue A, Spire C, Brun M, et al. (2010). Gene expression changes induced by PPAR gamma agonists in animal and human liver. PPAR Res 2010:325183.
208. Ross GD, Větvička V, Yan J, et al. (1999). Therapeutic intervention with complement and beta-glucan in cancer. Immunopharmacology 42:61–74.
209. Rowland IR, Gangolli SD. 1999. Role of gastrointestinal flora in the metabolic and toxicological activities of xenobiotics. General and Applied Toxicology. 2nd ed. London:Macmillan Publishers Ltd.
210. Rumney CJ, Rowland IR, Coutts TM, et al. (1993). Effects of risk-associated human dietary macrocomponents on processes related to carcinogenesis in human-flora-associated (HFA) rats. Carcinogenesis 14:79–84.
211. Sabater-Vilar M, Malekinejad H, Selman M, et al. (2007). In vitro assessment of adsorbents aiming to prevent deoxynivalenol and zearalenone mycotoxicoses. Mycopathologia 163:81–90.
212. Salvesen GS, Renatus M. (2002). Apoptosome:the seven-spoked death machine. Developmental Cell 2:256–7.
213. Sasaki T, Hiroki K, Yamashita Y. (2013). The role of epidermal growth factor receptor in cancer metastasis and microenvironment. Biomed Res Int 2013:546318.
214. Sazawal S, Hiremath G, Dhingra U, et al. (2006). Efficacy of probiotics in prevention of acute diarrhoea:a meta-analysis of masked, randomised, placebo-controlled trials. Lancet Infect Dis 6:374–82.
215. Schneider SM, Girard-Pipau F, Filippi J, et al. (2005). Effects of Saccharomyces boulardii on fecal short-chain fatty acids and microflora in patients on long-term total enteral nutrition. World J Gastroenterol 11:6165.
216. Schwartz B, Hadar Y. (2014). Possible mechanisms of action of mushroom-derived glucans on inflammatory bowel disease and associated cancer. Annals Translational Medicine 2:1–11.
217. Scott J, Rébeillé F, Fletcher J. (2000). Folic acid and folates:the feasibility for nutritional enhancement in plant foods. J Sci Food Agri 80:795–824.
218. Scott JM. (1999). Folate and vitamin B12. Proc Nutr Soc 58:441–8.
219. Serban DE. (2014). Gastrointestinal cancers:influence of gut microbiota, probiotics and prebiotics. Cancer Lett 345:258–70.
220. Sethi S, Ziouzenkova O, Ni H, et al. (2002). Oxidized omega-3 fatty acids in fish oil inhibit leukocyte-endothelial interactions through activation of PPAR alpha. Blood 100:1340–6.
221. Seyoum E, Selhub J. (1998). Properties of food folates determined by stability and susceptibility to intestinal pteroylpolyglutamate hydrolase action. J Nutr 128:1956–60.
222. Shapira I, Sultan K, Lee A, Taioli E. (2013). Evolving concepts:how diet and the intestinal microbiome act as modulators of breast malignancy. ISRN Oncol 2013:693920.
223. Sheflin AM, Whitney AK, Weir TL. (2014). Cancer-promoting effects of microbial dysbiosis. Curr Oncol Rep 16:406.
224. Sheu SH, Kaya T, Waxman DJ, Vajda S. (2005). Exploring the binding site structure of the PPAR gamma ligand-binding domain by computational solvent mapping. Biochemistry 44:1193–209.
225. Shin DY, Na II, Kim CH, et al. (2014). EGFR mutation and brain metastasis in pulmonary adenocarcinomas. J Thorac Oncol 9:195–9.
226. Shokri H, Asadi F, Khosravi AR. (2008). Isolation of beta-glucan from the cell wall of Saccharomyces cerevisiae. Nat Prod Res 22:414–21.
227. Shpitz B, Bomstein Y, Mekori Y, et al. (1997). Proliferating cell nuclear antigen as a marker of cell kinetics in aberrant crypt foci, hyperplastic polyps, adenomas, and adenocarcinomas of the human colon. Am J Surg 174:425–30.
228. Sivignon A, de Vallee A, Barnich N, et al. (2015). Saccharomyces cerevisiae CNCM I-3856 prevents colitis induced by AIEC bacteria in the transgenic mouse model mimicking Crohn’s disease. Inflamm Bowel Dis 21:276–86.
229. 2+ signaling and apoptosis. J. Bioenerg Biomembr 32:35–46.
230. Smith AD, Kim YI, Refsum H. (2008). Is folic acid good for everyone? Am J Clin Nutr 87:517–33.
231. Smith IM, Baker A, Arneborg N, Jespersen L. (2015). Non‐Saccharomyces yeasts protect against epithelial cell barrier disruption induced by Salmonella enterica subsp. enterica serovar Typhimurium. Let Appl Microbiol 61:491–7.
232. Smith IM, Christensen JE, Arneborg N, Jespersen L. (2014). Yeast modulation of human dendritic cell cytokine secretion:an in vitro study. PLoS One 9:e96595.
233. Soares RL. (2014). Irritable bowel syndrome:a clinical review. World J Gastroenterol 20:12144–60.
234. Sobhani I, Tap J, Roudot-Thoraval F, et al. (2011). Microbial dysbiosis in colorectal cancer (CRC) patients. PLoS One 6:e16393.
235. Sougioultzis S, Simeonidis S, Bhaskar KR, et al. (2006). Saccharomyces boulardii produces a soluble anti-inflammatory factor that inhibits NF-κB-mediated IL-8 gene expression. Biochem Biophysical Res Commun 343:69–76.
236. Soyturk M, Saygili SM, Baskin H, et al. (2012). Effectiveness of Saccharomyces boulardii in a rat model of colitis. World J Gastroenterol 18:6452–60.
237. Su CG, Wen X, Bailey ST, et al. (1999). A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response. J Clin Investig 104:383.
238. Suk K, Kim YH, Chang I, et al. (2001). IFNalpha sensitizes ME-180 human cervical cancer cells to TNFalpha-induced apoptosis by inhibiting cytoprotective NF-kappaB activation. FEBS Lett 495:66–70.
239. Sullivan Å, Nord C. (2002). The place of probiotics in human intestinal infections. Int J Antimicrob Agents 20:313–19.
240. Sweeney MR, McPartlin J, Scott J. (2007). Folic acid fortification and public health:report on threshold doses above which unmetabolised folic acid appear in serum. BMC Public Health 7:41.
241. Swidsinski A, Loening–Baucke V, Verstraelen H, et al. (2008). Biostructure of fecal microbiota in healthy subjects and patients with chronic idiopathic diarrhea. Gastroenterology 135:568–79.
242. Takata Y, Shrubsole MJ, Li H, et al. (2014). Plasma folate concentrations and colorectal cancer risk:a case-control study nested within the Shanghai Men’s Health Study. Int J Cancer 135:2191–8.
243. Thakur S, Thakur SD, Wani NA, Kaur J. (2014). Reduced expression of folate transporters in kidney of a rat model of folate oversupplementation. Genes Nutr 9:1–12.
244. Tiago FC, Porto BA, Ribeiro NS, et al. (2015). Effect of Saccharomyces cerevisiae strain UFMG A-905 in experimental model of inflammatory bowel disease. Benef Microbes 6:807–15.
245. Tien MT, Girardin SE, Regnault B, et al. (2006). Anti-inflammatory effect of Lactobacillus casei on Shigella-infected human intestinal epithelial cells. J Immunol 176:1228–37.
246. Toma MM, Raipulis J, Kalnina I, Rutkis R. (2005). Does probiotic yeast act as antigenotoxin? Food Technol Biotechnol 43:301–5.
247. Tsimmerman IS. (2013). [Eubiosis and dysbiosis of gastrointestinal tract:myths and reality]. Klin Med (Mosk) 91:4–11.
248. Tsuei J, Chau T, Mills D, Wan YJ. (2014). Bile acid dysregulation, gut dysbiosis, and gastrointestinal cancer. Exp Biol Med (Maywood) 239:1489–504.
249. Uemura N, Okamoto S, Yamamoto S, et al. (2001). Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 345:784–9.
250. Ulrich CM, Potter JD. (2006). Folate supplementation:too much of a good thing? Cancer Epidemiol Biomarkers Prev 15:189–93.
251. van der Aa Kühle A, Skovgaard K, Jespersen L. (2005). In vitro screening of probiotic properties of Saccharomyces cerevisiae var. boulardii and food-borne Saccharomyces cerevisiae strains. Int J Food Microbiol 101:29–39.
252. Vandenplas Y, Brunser O, Szajewska H. (2009). Saccharomyces boulardii in childhood. Eur J Pediatr 168:253–65.
253. VanEenwyk J, Davis FG, Colman N. (1992). Folate, vitamin C, and cervical intraepithelial neoplasia. Cancer Epidemiol Biomarkers Prev 1:119–24.
254. Venturi M, Hambly RJ, Glinghammar B, et al. (1997). Genotoxic activity in human faecal water and the role of bile acids:a study using the alkaline comet assay. Carcinogenesis 18:2353–9.
255. Vetvicka V. (2001). β-Glucans as immunomodulators. JANA 3:31–4.
256. Vetvicka V, Terayama K, Mandeville R, et al. (2002). Pilot study:orally-administered yeast β-1,3-glucan prophylactically protects against anthrax infection and cancer in mice. JANA 5:1–6.
257. Vetvicka V, Volny T, Saraswat-Ohri S, et al. (2007). Glucan and resveratrol complex-possible synergistic effects on immune system. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 151:41–6.
258. Vitale G, Zappavigna S, Marra M, et al. (2012). The PPAR-γ agonist troglitazone antagonizes survival pathways induced by STAT-3 in recombinant interferon-β treated pancreatic cancer cells. Biotechnol Adv 30:169–84.
259. Vohra A, Satyanarayana T. (2012). Probiotic yeasts. In:Satyanarayana T, Johri BN, eds. Microorganisms in sustainable agriculture and biotechnology. Netherlands:Springer.
260. Volman JJ, Ramakers JD, Plat J. (2008). Dietary modulation of immune function by beta-glucans. Physiol Behav 94:276–84.
261. Wan Y, Xin Y, Zhang C, et al. (2014). Fermentation supernatants of Lactobacillus delbrueckii inhibit growth of human colon cancer cells and induce apoptosis through a caspase 3-dependent pathway. Oncol Lett 7:1738–42.
262. Wei MM, Bailey LB, Toth JP, Gregory JF, 3rd. (1996). Bioavailability for humans of deuterium-labeled monoglutamyl and polyglutamyl folates is affected by selected foods. J Nutr 126:3100–8.
263. Weiler F, Schmitt MJ. (2003). Zygocin, a secreted antifungal toxin of the yeast Zygosaccharomyces bailii, and its effect on sensitive fungal cells. FEMS Yeast Res 3:69–76.
264. Wells A. (2000). Tumor invasion:role of growth factor-induced cell motility. Adv Cancer Res 78:31–101.
265. Weston SA, Parish CR. (1991). Modification of lymphocyte migration by mannans and phosphomannans. Different carbohydrate structures control entry of lymphocytes into spleen and lymph nodes. J Immunol 146:4180–6.
266. WHO/FAO. (2002). Guidelines for the evaluation of probiotics in food. London:Food and Agriculture Organization of the United Nations and World Health Organization Working Group.
267. Witthoft CM, Arkbage K, Johansson M, et al. (2006). Folate absorption from folate-fortified and processed foods using a human ileostomy model. Br J Nutr 95:181–7.
268. Witthuhn R, Schoeman T, Britz T. (2005). Characterisation of the microbial population at different stages of Kefir production and Kefir grain mass cultivation. Int Dairy J 15:383–9.
269. Xuan C, Shamonki JM, Chung A, et al. (2014). Microbial dysbiosis is associated with human breast cancer. PLoS One 9:e83744.
270. Yajima K, Hirose H, Fujita H, et al. (2003). Combination therapy with PPARgamma and PPARalpha agonists increases glucose-stimulated insulin secretion in db/db mice. Am J Physiol Endocrinol Metab 284:E966–71.
271. Yeretssian G. (2012). Effector functions of NLRs in the intestine:innate sensing, cell death, and disease. Immunol Res 54:25–36.
272. Zekovic DB, Kwiatkowski S, Vrvic MM, et al. (2005). Natural and modified (1-->3)-beta-D-glucans in health promotion and disease alleviation. Crit Rev Biotechnol 25:205–30.
273. Zhang M, Fan X, Fang B, et al. (2015). Effects of Lactobacillus salivarius Ren on cancer prevention and intestinal microbiota in 1,2-dimethylhydrazine-induced rat model. J Microbiol 53:398–405.
274. Zhang M, Qiao X, Zhao L, et al. (2011). Lactobacillus salivarius REN counteracted unfavorable 4-nitroquinoline-1-oxide-induced changes in colonic microflora of rats. J Microbiol 49:877–83.
275. Zhang M, Wang F, Jiang L, et al. (2013). Lactobacillus salivarius REN inhibits rat oral cancer induced by 4-nitroquioline 1-oxide. Cancer Prev Res (Phila) 6:686–94.
276. Zhong L, Zhang X, Covasa M. (2014). Emerging roles of lactic acid bacteria in protection against colorectal cancer. World J Gastroenterol 20:7878–86.